LONDON, ENGLAND — April 15, 2002 — Symbicort Turbohaler® (budesonide/eformoterol) from AstraZeneca has been granted a license in the United Kingdom for use in adolescents (age 12 years and older), providing healthcare professionals with a highly effective, adjustable treatment option.
"Any doctor or nurse treating teenage asthma patients will tell you of the difficulties they face," commented Dermot Ryan, MD a member of the General Practice Airways Group.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!